Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in SeptemberPRNewsWire • 08/28/20
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic DermatitisPRNewsWire • 08/13/20
Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological DiseasesPRNewsWire • 07/31/20
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 TreatmentPRNewsWire • 06/30/20
Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White PaperPRNewsWire • 06/15/20
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology ConditionsPRNewsWire • 06/08/20
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory BoardPRNewsWire • 05/22/20
Emerging Markets Report: Hoth Therapeutics is Working on a Potential Coronavirus Vaccine (COVID-19)GlobeNewsWire • 03/24/20